References
- SullyBGJuliousSANichollJA reinvestigation of recruitment to randomised, controlled, multicenter trials: a review of trials funded by two UK funding agenciesTrials20131416623758961
- McDonaldAMKnightRCCampbellMKWhat influences recruitment to randomised controlled trials? A review of trials funded by two UK funding agenciesTrials20067916603070
- National Research Council Panel on Handling Missing Data in Clinical TrialsThe Prevention and Treatment of Missing Data in Clinical TrialsWashington, DCThe National Academy Press2010
- UngerJMGralowJRAlbainKSRamseySDHershmanDLPatient income level and cancer clinical trial participation: a prospective survey studyJAMA Oncol20162113713926468994
- The Society for Women’s Health Research, United States Food and Drug Administration Office of Women’s HealthDialogues on diversifying clinical trials. Successful strategies for engaging women and minorities in clinical trials2011 Available from: http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/WomensHealthResearch/UCM334959.pdfAccessed November 2, 2016
- VinaERUtsetTOHannonMJMasiCMRobertsNKwohCKRacial differences in treatment preferences among lupus patients: a two-site studyClin Exp Rheumatol201432568068825084365
- CooperAAConklinLRDropout from individual psychotherapy for major depression: a meta-analysis of randomized clinical trialsClin Psychol Rev201540576526067572
- LimSSBayaklyARHelmickCGGordonCEasleyKADrenkardCThe incidence and prevalence of systemic lupus erythematosus, 2002–2004: the Georgia Lupus RegistryArthritis Rheumatol201466235736824504808
- SomersECMarderWCagnoliPPopulation-based incidence and prevalence of systemic lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance programArthritis Rheumatol201466236937824504809
- FurieRPetriMZamaniOA phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosusArthritis Rheum201163123918393022127708
- FurieRKhamashtaMMerrillJTAnifrolumab, an anti-interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosusArthritis Rheumatol201769237638628130918
- GoldbergAGeppertTSchiopuEDose-escalation of human anti-interferon-alpha receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label studyArthritis Res Ther2014161R5724559157
- RathertCWyrwichMDBorenSAPatient-centered care and outcomes: a systematic review of the literatureMed Care Res Rev201370435137923169897
- Institute of Medicine (US), Committee on Quality of Health Care in AmericaCrossing the Quality Chasm: A New Health System for the 21st CenturyWashington, DCNational Academy Press2001
- KostRGLeeLMYessisJWesleyRAHendersonDKCollerBSAssessing participant-centered outcomes to improve clinical researchN Engl J Med2013369232179218124304050
- WendlerDKrohmalBEmanuelEJGradyCESPRIT GroupWhy patients continue to participate in clinical researchArch Intern Med2008168121294129918574086
- CostenbaderKHBromeDBlanchDFactors determining participation in prevention trials among systemic lupus erythematosus patients: a qualitative studyArthritis Rheum2007571495517266094